Bumetanide
Who holds supplier records for Bumetanide? 10 organisations hold a current record for Bumetanide: an active US FDA Type II Drug Master File or a CEP. A further 1 organisation has only historical (inactive) DMF filings. 8 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: India (4), China (3) and Italy (2); not recorded for 1.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Bumetanide: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/bumetanide
Reading the evidence
- 10 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- 7 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Bumetanide expires 14 May 2045. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (10)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Bumetanide. Country is the organisation's recorded country, not necessarily the manufacturing site.
- HAINAN POLY PHARM CO LTDCEP Company GMP cert on recordActive DMF 40272 · latest filing Jul 2024
- INDUSTRIALE CHIMICA SRLItalyCEP Company GMP cert on recordActive DMF 24750 · latest filing Mar 2011
- MEDILUX LABORATORIES PVT LTDIndiaCEP Company GMP cert on recordActive DMF 41830 · latest filing May 2025
- MSN Laboratories Private LimitedIndiaCEP Company GMP cert on recordActive DMF 33915 · latest filing Jun 2019
- OLON SPAItalyCEP Company GMP cert on recordActive DMF 10994 · latest filing Jul 1994
- SOLARA ACTIVE PHARMA SCIENCES LTDIndiaCEP Company GMP cert on recordActive DMF 33261 · latest filing Oct 2018
- Unichem Laboratories Ltd.IndiaCEP Company GMP cert on recordActive DMF 42047 · latest filing Jun 2025
- Allsino Pharmaceutical Co., Ltd.ChinaActive DMF 43352 · latest filing Jun 2026
- Guilin Pharmaceutical Co., Ltd.ChinaActive DMF 8682 · latest filing Jul 1990
- Suzhou Lixin Pharmaceutical Co., Ltd.ChinaCEP
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Valid CEP holder entries (8)
Certificates of Suitability on the EDQM register for Bumetanide, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.
| Holder | Country | Certificate | Issued | EU GMP at holder's address |
|---|---|---|---|---|
| OLON S.P.A. Rodano | IT | CEP 1998-151 - Rev 08 Bumetanide | Aug 2026 | Inspected Mar 2025 Italy |
| SUZHOU LIXIN PHARMACEUTICAL CO., LTD. Suzhou | CN | CEP 2024-381 - Rev 00 Bumetanide | Dec 2025 | Inspected Aug 2023 France, outside 3-year window |
| MEDILUX LABORATORIES PRIVATE LIMITED Pithampur | IN | CEP 2024-248 - Rev 00 Bumetanide | Jul 2025 | Inspected Nov 2025 Germany |
| HAINAN POLY PHARMACEUTICAL COMPANY LIMITED Haikou | CN | CEP 2024-510 - Rev 00 Bumetanide | Jun 2025 | Inspected Mar 2024 Netherlands |
| UNICHEM LABORATORIES LIMITED Mumbai | IN | CEP 2017-100 - Rev 03 Bumetanide | Nov 2024 | — |
| SOLARA ACTIVE PHARMA SCIENCES LIMITED Chennai | IN | CEP 2022-034 - Rev 00 Bumetanide | Aug 2024 | — |
| INDUSTRIALE CHIMICA S.R.L. Saronno | IT | CEP 2001-293 - Rev 06 Bumetanide | Mar 2024 | Inspected Oct 2025 Italy |
| MSN LABORATORIES PRIVATE LIMITED Rudraram Village | IN | R0-CEP 2020-151 - Rev 00 Bumetanide | Mar 2022 | — |
The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.
Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.
Historical records (1)
Organisations whose Type II DMFs for Bumetanide are no longer active. These show a past filing, not current supply.
Show all 1 historical record
- Spain · Inactive DMF 8435 · filed Feb 1990
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (48 listed products contain Bumetanide). The latest listed patent expires 14 May 2045. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Overview
Bumetanide is a potent loop diuretic used to treat edema associated with heart failure, liver cirrhosis, and renal disease, including the nephrotic syndrome. It works by inhibiting the sodium-potassium-chloride symporter in the thick ascending limb of the loop of Henle, thereby increasing urine production.
Chemical identity
- IUPAC name
- 3-(butylamino)-4-phenoxy-5-sulfamoylbenzoic acid
- Canonical SMILES
- CCCCNC1=C(C(=CC(=C1)C(=O)O)S(=O)(=O)N)OC2=CC=CC=C2
- InChIKey
- MAEIEVLCKWDQJH-UHFFFAOYSA-N
- Synonyms
- Bumex API, bumex, enbumyst, pf-1593, pf1593, ro-10-6338, ro-106338, ro10-6338, s-95008., s95008.
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Loop Diuretic
- Physiologic effect
- Increased Diuresis at Loop of Henle
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Bumetanide?
10 organisations hold an active US FDA Type II Drug Master File or a CEP for Bumetanide: HAINAN POLY PHARM CO LTD, INDUSTRIALE CHIMICA SRL (Italy), MEDILUX LABORATORIES PVT LTD (India), MSN Laboratories Private Limited (India), OLON SPA (Italy), SOLARA ACTIVE PHARMA SCIENCES LTD (India), Unichem Laboratories Ltd. (India) and Allsino Pharmaceutical Co., Ltd. (China), and 2 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Bumetanide Drug Master Files are active?
HAINAN POLY PHARM CO LTD (DMF 40272), INDUSTRIALE CHIMICA SRL (DMF 24750), MEDILUX LABORATORIES PVT LTD (DMF 41830), MSN Laboratories Private Limited (DMF 33915), OLON SPA (DMF 10994), SOLARA ACTIVE PHARMA SCIENCES LTD (DMF 33261), Unichem Laboratories Ltd. (DMF 42047) and Allsino Pharmaceutical Co., Ltd. (DMF 43352) and 1 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
What do the historical Bumetanide records mean?
1 organisation has only inactive Type II DMFs for Bumetanide. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
Does Bumetanide have a European Certificate of Suitability?
Yes. 8 organisations hold a valid CEP for Bumetanide on the EDQM register, including OLON S.P.A. Rodano (IT), SUZHOU LIXIN PHARMACEUTICAL CO., LTD. Suzhou (CN), MEDILUX LABORATORIES PRIVATE LIMITED Pithampur (IN), HAINAN POLY PHARMACEUTICAL COMPANY LIMITED Haikou (CN), UNICHEM LABORATORIES LIMITED Mumbai (IN) and SOLARA ACTIVE PHARMA SCIENCES LIMITED Chennai (IN) and 2 more. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.
Does the FDA Orange Book list patents for products containing Bumetanide?
Yes. The latest patent listed for an approved US product containing Bumetanide expires 14 May 2045, across 48 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Bumetanide supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Bumetanide?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.